Literature DB >> 1682589

Determinants of HIV disease progression: six-year longitudinal study in the Edinburgh haemophilia/HIV cohort.

P Simmonds1, D Beatson, R J Cuthbert, H Watson, B Reynolds, J F Peutherer, J V Parry, C A Ludlam, C M Steel.   

Abstract

Markers of immune function present before infection may determine the subsequent course of disease in HIV-infected individuals. In 1983, we measured immune function in a group of haemophiliacs in Edinburgh. In 1984, 18 of these patients became infected with HIV-1 from contaminated factor VIII. We have followed-up these patients since their seroconversion. The rate of disease progression, as assessed by the appearance or not of AIDS symptoms or signs within five years of seroconversion, was related both to the concentration of total plasma IgM before exposure to infection and to the pattern of specific IgM and IgA anti-HIV response around the time of IgG seroconversion. Disease progression also correlated with concentrations of plasma interleukin-2 receptor (a marker of lymphocyte activation) and with the number and percentage of circulating DR + ve (activated) T cells. Our findings show that the extent of host immune reactivity, which may be genetically determined, is a powerful factor in the pathogenesis of HIV-associated disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1682589     DOI: 10.1016/0140-6736(91)92029-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  13 in total

1.  Minocycline suppresses activation of nuclear factor of activated T cells 1 (NFAT1) in human CD4+ T cells.

Authors:  Gregory L Szeto; Joel L Pomerantz; David R M Graham; Janice E Clements
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

2.  Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease.

Authors:  Shailesh K Choudhary; Nienke Vrisekoop; Christine A Jansen; Sigrid A Otto; Hanneke Schuitemaker; Frank Miedema; David Camerini
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

3.  Early levels of CD4, neopterin, and beta 2-microglobulin indicate future disease progression.

Authors:  M Shi; J M Taylor; J L Fahey; D R Hoover; A Muñoz; L A Kingsley
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

Review 4.  T helper cell activation and human retroviral pathogenesis.

Authors:  K F Copeland; J L Heeney
Journal:  Microbiol Rev       Date:  1996-12

5.  The probability of acquiring primary Toxoplasma infection in HIV-infected patients: results of an 8-year retrospective study.

Authors:  I Reiter-Owona; R Bialek; J K Rockstroh; H M Seitz
Journal:  Infection       Date:  1998 Jan-Feb       Impact factor: 3.553

6.  Antiretroviral treatment reverses HIV-induced reduction in the expression of surface antigens on alveolar macrophages in AIDS patients.

Authors:  D H Bray; S B Squire; A Kawana; M A Johnson; L W Poulter
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

7.  Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 x 10(6)/l, AIDS, and death from AIDS?

Authors:  S Lindbäck; C Broström; A Karlsson; H Gaines
Journal:  BMJ       Date:  1994-12-10

Review 8.  Factor VIII, HIV and AIDS in haemophiliacs: an analysis of their relationship.

Authors:  E Papadopulos-Eleopulos; V F Turner; J M Papadimitriou; D Causer
Journal:  Genetica       Date:  1995       Impact factor: 1.082

9.  Flow cytometric immunofluorescence assay for detection of antibodies to human immunodeficiency virus type 1 using insoluble precursor forms of recombinant polyproteins as carriers and antigens.

Authors:  Y W Hu; P Birch; E Balaskas; A Zeibdawi; V Scalia; S A Thériault-Valin; P Gill; M T Aye
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

10.  Clinical significance of serum 2,5-oligoadenylate synthetase and soluble interleukin-2 receptor in hemophiliacs positive and negative for human immunodeficiency virus type 1.

Authors:  J Matsuda; M Gotoh; K Gohchi; M Tsukamoto; N Saitoh; T Kinoshita
Journal:  Clin Diagn Lab Immunol       Date:  1994-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.